ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1493	National Cancer Institute	Html	en	Oropharyngeal Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of oropharyngeal cancer.	neck radiotherapy 0.359364 locally advanced head 0.471621 Engl J Med 0.53665 American Cancer Society 0.443811 well-lateralized oropharyngeal cancer 0.401103 neck radiation therapy 0.384516 Int J Radiat 0.508851 neck cancer patients 0.486158 squamous cell cancer 0.411067 Radiat Oncol Biol 0.753309 DeVita VT Jr 0.383261 Natl Cancer Inst 0.447951 neck cancers 0.433823 Clin Cancer Res 0.390283 radiation therapy 0.610067 human papillomavirus 0.44587 smoking-related oropharyngeal cancer 0.443579 HPV-positive oropharyngeal cancer 0.448716 et al. 0.570118 Mendenhall WM 0.369324 Cancer Genet Cytogenet 0.359903 Head Neck 0.484421 index nonoropharyngeal cancer 0.350094 Oropharyngeal tumors 0.352557 index oropharyngeal SCC 0.386084	neck SCC 0.359598 oropharyngeal cancers 0.476599 HPV-positive oropharyngeal cancers 0.469127 anterior tonsillar pillar 0.378606 Cancer Epidemiol Biomarkers 0.378376 neck squamous cell 0.377126 head 0.534685 PUBMED Abstract 0.462256 early-stage oropharyngeal cancer 0.392101 Otolaryngol Head Neck 0.404239 index oropharyngeal cancers 0.372661 -positive oropharyngeal cancers 0.363257 neck retinoid chemoprevention 0.355793 Abstract 0.60039 Clin Oncol 0.357598 Oncol Biol Phys 0.772447 squamous cell carcinomas 0.385763 primary tumor 0.372966 field cancerization 0.370643 neck cancer 0.957961 neck tumors 0.340144 oropharyngeal cancer 0.807108 oropharyngeal SCC 0.391565 oropharyngeal cancer incidence 0.417437	CLICK HERE
1558	National Cancer Institute	Html	en	Endometrial Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease.	cancer treatment 0.459672 cancer prevention trials 0.519855 estrogen 0.503683 endometrial cancer prevention 0.633127 protective factors 0.494311 following PDQ summaries 0.487054 PDQ cancer information 0.583616 estrogen receptor modulators 0.479388 oral contraceptives increases 0.455046 uterus 0.455824 clinical trials 0.591442 cancer information summary 0.536389 breast cancer prevention 0.515055 cancer patients 0.456862 cancer risk factor 0.514935 NCI’s PDQ 0.460213 metabolic syndrome 0.469608 Clinical Trials section 0.455747 NCI PDQ cancer 0.511939 endometrial hyperplasia 0.525569 hormone replacement therapy 0.4814 new cases 0.45495 estrogen levels 0.496361 cancer risk factors 0.513284	Cancer prevention 0.648371 cancer protective factor 0.491722 high estrogen levels 0.479463 Cancer Information Service 0.48404 polycystic ovary syndrome 0.484739 prevention clinical trials 0.493334 Prevention Editorial Board 0.485326 treatment clinical trials 0.456257 National Cancer Institute 0.542099 endometrial cancer 0.951484 African American women 0.525683 estrogen therapy 0.459908 higher risk 0.454955 postmenopausal women 0.557323 Cancer Care page 0.476271 PDQ database 0.456704 PDQ summary 0.495085 combination oral contraceptives 0.477913 cancer clinical trials 0.489805 risk factors 0.587492 nonpolyposis colon cancer 0.481746 cancer information summaries 0.48866 comprehensive cancer information 0.488387 risk 0.63452	CLICK HERE
1846	National Cancer Institute	Html	es	Tratamiento del carcinoma de corteza suprarrenal (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del carcinoma de corteza suprarrenal.	Compton CC 0.317328 Hammer GD 0.357944 resection vs chemotherapy 0.309791 Sin embargo 0.386449 estadificación ensat 0.311064 largo plazo 0.314068 treatment utilization 0.307637 7th ed 0.317264 estadificación ajcc 0.311961 corteza suprarrenal benignos 0.333736 adrenal cortical carcinoma 0.326878 Instituto Nacional 0.323164 Radiat Oncol Biol 0.331552 Zaggia B 0.315343 Ardito A 0.314362 Terzolo M 0.35082 Basic Science 0.331876 Else T 0.335075 Clinical review 0.338841 corteza suprarrenal benignas 0.333037 ENSAT staging system 0.311888 Arch Surg 0.319608 Griffith K 0.315391 Feng M 0.318852 Fassnacht M 0.481992	Clin Endocrinol Metab 0.365561 estadio ii 0.316817 metástasis pulmonar 0.312599 Pfreundner L 0.316104 Angeli A 0.316386 Cancer Staging Manual 0.333671 adrenocortical carcinoma using 0.342814 National Cancer Institute 0.309404 PDQ Tratamiento 0.316742 New York 0.405075 Physician Data Query 0.30836 adrenocortical carcinoma 0.972403 Oncol Biol Phys 0.332857 Langenbecks Arch Surg 0.312314 Allolio B 0.353761 with adrenocortical carcinoma 0.336171 Byrd DR 0.316426 Union Internationale Contre 0.309764 American Joint Committee 0.309683 Sabolch A 0.315391 Ther Phys Biol 0.311534 Recurrent or metastatic 0.308748 Clinical Concepts 0.340059 AJCC Cancer Staging 0.33628	CLICK HERE
1881	National Cancer Institute	Html	es	Tratamiento del sarcoma de Ewing (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del Sarcoma de Ewing.	ewing sarcoma 0.997403 Ewing family 0.318421 Ewing's sarcoma family 0.369762 metastatic ewing sarcoma 0.318472 ewing óseo valor 0.311245 skeletal localized ewing 0.310397 Ewing Grupo 0.309837 non-metastatic ewing 0.310313 Ewing's Sarcoma Studies 0.319442 ewing óseo característica 0.311302 Ewing extraóseo 0.331665 Ewing sarcoma demonstrates 0.319966 Ewing sarcoma with 0.320002 localized ewing tumours 0.310538 localized ewing 0.369471 ewing-like sarcomas 0.313809 Children's Oncology Group 0.332597 ewing sarcoma family 0.424972 Ewing sarcoma patients 0.320654 with ewing 0.35586 Ewing's tumors with 0.311931 Ewing Sarcoma Study 0.321953 with localized ewing 0.320841 primary ewing 0.310256 extraskeletal ewing sarcoma 0.318994	Ewing's Sarcoma Study 0.335323 synovial sarcoma 0.309759 cooperative ewing sarcoma 0.431437 Ewing sarcoma under 0.319395 EWSR1-rearranged Ewing 0.309748 localized ewing tumor 0.320103 ewing extraóseo sarcoma 0.320923 osseous ewing 0.30998 Pediatr Blood Cancer 0.363663 ewing sarcoma defines 0.332159 Intergroup Cooperative Ewing 0.343374 Ewing Sarcoma Studies 0.337882 Genes Chromosomes Cancer 0.320148 ewing's sarcoma 0.626467 Ewing óseo 0.324425 gen ewsr1 0.309831 ewing's tumors 0.326472 secondary ewing 0.310067 Pediatr Hematol Oncol 0.310262 Clin Oncol 0.365031 multifocal ewing sarcoma 0.318953 ewing tumors 0.399514 congenital ewing sarcoma 0.318921 Ewing sarcoma susceptibility 0.318556	CLICK HERE
2071	National Cancer Institute	Html	es	Cirugía para reducir el riesgo de cáncer de seno	Hoja informativa que describe las clases de cirugía para reducir el riesgo de cáncer de seno y las situaciones en las que se puede pensar en esas operaciones.	Surgical Adjuvant Breast 0.526694 PROSE Study Group 0.516256 cáncer invasor 0.567762 brca1 or brca2 0.538495 mastectomía subcutánea 0.530865 Preventing breast 0.511838 Breast Cancer Research 0.523551 risk-reducing surgery 0.507962 with brca1 or 0.509298 brca2 mutation 0.564149 breast screening with 0.51472 Preventive Services Task 0.512338 mastectomy reduces breast 0.516804 alta penetrancia 0.508455 risk after smaller 0.509063 Friebel T 0.508008 PubMed Abstract 0.952028 Clinical Oncology 0.653359 Cancer Journal 0.515034 BRCA2 mutation carriers 0.554396 early breast cancer 0.539203 ¿Cuáles mujeres 0.517292 bilateral mastectomy 0.517477 BRCA2 mutations detected 0.508495 alto riesgo 0.656597	Wickerham DL 0.51571 an overview 0.508367 Costantino JP 0.515178 Cancer Risk Assessment 0.519342 Rebbeck TR 0.508232 developing invasive breast 0.513495 antecedentes familiares 0.554456 riesgo promedio 0.539499 or brca2 mutations 0.536318 breast cancer risk 0.617067 mutation carriers with 0.509322 gen pten 0.510383 breast cancer 0.801718 Breast Cancer Trialists 0.522907 Services Task Force 0.511925 prophylactic mastectomy 0.591377 mujeres portadoras 0.533011 gen brca1 0.561202 contralateral prophylactic mastectomy 0.534028 Cancer Institute 0.511805 Clinical Cancer Research 0.516971 gen brca2 0.561192 gen tp53 0.518098 New England Journal 0.535054	CLICK HERE
3413	National Cancer Institute	Html	en	Treatment Prevents Chemotherapy Side Effects for Children with Cancer	Adding aprepitant to the anti-nausea drug ondansetron, with or without dexamethasone, effectively prevents chemotherapy-induced nausea and vomiting in children.	Lancet Oncology 0.402095 approximately one-quarter 0.400434 Approximately half 0.380915 individual chemotherapy regimens 0.640029 pediatric oncologists 0.386544 primary endpoint 0.376989 accompanying editorial 0.359286 control group 0.648089 chemotherapy 0.797555 highly emetogenic chemotherapy 0.635176 pediatric patients 0.446593 pediatric dosing 0.38895 cancer therapy 0.375879 South Korea 0.360387 Final results 0.390611 poorer outcomes 0.360045 delayed phase 0.536277 well-designed anti-emetic study 0.496684 children 0.367409 pediatric anti-emetic regimens 0.524869 steroid dexamethasone 0.449436 retrospective reports 0.357625 Hyoung Jin Kang 0.507923 treatment-limiting complications 0.376302	moderate risk 0.374131 Richard Gralla 0.361364 vomiting 0.627585 anti-nausea drug 0.394817 clinical trial 0.39616 chemotherapy-induced nausea 0.735879 Fifty-one percent 0.401703 cancer patients 0.390213 trial results 0.359251 aprepitant group 0.947977 complete response 0.53189 study medications 0.371063 febrile neutropenia 0.569771 Seoul National University 0.506591 neurokinin-1 receptor antagonist 0.536858 serotonin receptor 0.391814 neutrophil count 0.368149 Pediatric Oncology Branch 0.516455 chemotherapy regimen patients 0.648708 antiemetic rescue medication—medication 0.520408 common adverse events 0.501689 Secondary endpoints 0.373589 Melinda Merchant 0.355445	CLICK HERE
3432	National Cancer Institute	Html	es	Formaldehído y el riesgo de cáncer	Hoja informativa que trata sobre el formaldehído y su posible relación con el cáncer. Incluye recursos para consultar mayor información.	leucemia mieloide 0.978153 malignancies among workers 0.549063 TW Alexander Drive 0.542382 exterior-grade” pressed-wood 0.527538 cancers among workers 0.548254 Programa Nacional 0.567373 largo plazo 0.580439 Protección Ambiental 0.673926 Salud Ocupacional 0.583378 Mortality from 0.576068 Instituto Nacional 0.645898 Indoor Air 0.527731 pequeñas cantidades 0.52948 Lubin JH 0.573228 posibles efectos 0.584035 Estados Unidos 0.527658 PubMed Abstract 0.744149 Cancer Institute Cohort 0.547453 East West Highway 0.542743 International Agency 0.53583 Environmental Protection Agency 0.819165 probable carcinógeno 0.619447 Product Safety Commission 0.830336 among workers 0.572581 New Hampshire Avenue 0.541693	aislamiento uffi 0.536299 National Toxicology Program 0.804784 Drug Administration 0.579636 Environmental Health Sciences 0.548429 Occupational Environmental Medicine 0.553867 Mortality among 0.531703 Occupational Safety 0.816569 materiales aislantes 0.528932 British chemical workers 0.549313 Emergency Management Agency 0.637566 vías respiratorias 0.526175 National Cancer Institute 0.733699 National Institute 0.579158 aislamiento tipo uffi 0.553887 Health Administration 0.662185 Consumer Product Safety 0.833221 Indoor Environments Division 0.548156 corto plazo 0.574665 garment workers 0.530046 Blair A 0.564637 cabo estudios 0.530631 12.º informe 0.526826 Federal Emergency Management 0.627002 Institutos Nacionales 0.577211	CLICK HERE
15882	National Cancer Institute	Html	es	Cardo mariano (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del cardo mariano como tratamiento para personas con cáncer.	Silybum marianum 0.735385 Agarwal R 0.945743 cell lines 0.375003 cell growth 0.494513 prostate carcinoma du145 0.373715 DNA synthesis 0.442196 carcinoma cell 0.46955 silybum marianum l 0.361146 Inhibitory effect 0.390679 Agarwal C 0.386743 receptor modulator activity 0.356592 Mol Carcinog 0.378538 Cancer Res 0.59348 carcinoma cell growth 0.407562 prostate carcinoma cells 0.4865 Singh RP 0.367955 flavonoid antioxidant 0.678831 active constituent 0.382485 Antiproliferative effect 0.363827 lipid peroxidation 0.585387 Biochem Pharmacol 0.461277 chemopreventive effects 0.369648 cardo lechero 0.365629 patients with 0.374862 cell growth inhibition 0.393232	Sonnenbichler J 0.428511 prostate carcinoma 0.590474 Campos R 0.414926 Pharmacol Res 0.429959 protective effects 0.379153 Biophys Res Commun 0.50103 prostate-specific antigen with 0.369145 carcinoma du145 cells 0.397873 Biochem Biophys Res 0.508991 Silymarin effects 0.38621 Biomed Res Int 0.385769 Clin Biol Res 0.375557 insulin-like growth factor-binding 0.358425 stimulatory effects 0.357205 Zhao J 0.53049 Guerra R 0.490633 with cell growth 0.41107 comparison with 0.378495 silibinin inhibits 0.378656 Planta Med 0.529049 protects against 0.371646 Mutat Res 0.369799 from silybum marianum 0.396284 Res Commun 0.505421	CLICK HERE
16247	National Cancer Institute	Html	en	Examining the Effects of Presurgical Treatment for Prostate Cancer	In this study, men diagnosed with androgen-sensitive prostate cancer with intermediate- or high-risk features will be examined with mpMRI, undergo targeted biopsies, and be treated with neoadjuvant androgen deprivation therapy.	prostate tumors 0.614738 mpMRI scans 0.310993 new strategies 0.267582 potential tumor markers 0.311786 clinical trials 0.372782 targeted biopsy samples 0.322875 targeted lesions 0.294339 specific prostate lesions 0.476878 high-risk features 0.288054 newly diagnosed prostate 0.622232 metastatic prostate cancer 0.498919 prostate cancer cells 0.594259 surgically removed organs 0.312098 antiandrogen drug enzalutamide 0.322935 single imaging exam 0.312805 Dr. William Dahut 0.330786 systemic therapy 0.28819 neoadjuvant therapy 0.769289 aggressive prostate cancers 0.483417 protocol summary 0.275419 androgen-deprivation therapy 0.285401 NCI Center 0.275353 magnetic resonance imaging 0.315153 trial contact information 0.309223 United States 0.272406	intensive hormonal therapy 0.397524 high-risk prostate tumors 0.477739 prostatectomy specimens 0.282563 Treating Patients 0.272894 initial mpMRI scans 0.308885 high-risk prostate cancer 0.602491 radical prostatectomy 0.351855 NCI Clinical Trials 0.312784 common malignancy 0.274438 androgen-sensitive prostate cancer 0.480836 potential strategy 0.266185 Cancer Research 0.343151 anatomic imaging 0.268037 drug goserelin actetate 0.309432 targeted biopsies 0.292493 male sex hormones 0.320468 Goserelin Acetate 0.270879 high-risk disease 0.33068 prostate cancer 0.95691 neoadjuvant ADT 0.340784 aggressive disease 0.267926 prostate cancer recurrence 0.502931 specific lesions 0.287557 effective neoadjuvant therapy 0.348548	CLICK HERE
17173	National Cancer Institute	Html	es	Hongos medicinales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de los hongos medicinales como tratamiento para las personas con cáncer.	adjuvant immunochemotherapy with 0.310705 ganoderma lucidum 0.95261 Coriolus versicolor 0.338242 Ganoderma lucidum from 0.330019 triterpenoids from ganoderma 0.34341 from ganoderma spp 0.316446 extracted from ganoderma 0.316294 Se-enriched Ganoderma lucidum 0.325078 mushroom ganoderma lucidum 0.326878 cuáles pacientes 0.311657 adjuvant immunochemotherapy 0.310969 cells with immuno-stimulatory 0.308341 PSK may 0.326201 polysaccharides from ganoderma 0.316147 Ganoderma lucidum induces 0.347342 Oncol Rep 0.321721 Ganoderma lucidum polysaccharides 0.378912 Ganoderma lucidum mycelia 0.327066 pacientes supervivencia 0.312919 Ganoderma polysaccharides with 0.315786 patients with 0.347196 protein-bound polysaccharide psk 0.327993 lz-8 from ganoderma 0.316148 Ganoderma lucidum activities 0.328306 metabolites from ganoderma 0.315749	ganoderma lingzhi wu 0.315644 PSK quizás 0.327997 Ganoderma lucidum spores-induced 0.32738 from ganoderma lucidum 0.482816 oficiales ganoderma lucidum 0.327352 immunochemotherapy with psk 0.347115 PSK therapies 0.324706 isolated from ganoderma 0.330138 commercial ganoderma 0.31277 lucidum suppresses angiogenesis 0.315879 Ganoderma based 0.312698 ganoderma sinense zhao 0.315248 Mol Med 0.308288 gastric cancer 0.374999 extract from ganoderma 0.316948 immunochemotherapy with polysaccharide 0.311361 breast cancer 0.314008 Mushroom Science 0.307833 Ganoderma lingzhi from 0.316096 ganoderma lucidum triterpenoids 0.328168 PSK potencia 0.327619 Ganoderma lingzhi 0.323758 leukemia cells 0.314028 estudios cáncer 0.308153	CLICK HERE